Toward individualized cholesterol-lowering treatment in end-stage renal disease.

Silbernagel, Günther; Baumgartner, Iris; Wanner, Christoph; März, Winfried (2014). Toward individualized cholesterol-lowering treatment in end-stage renal disease. Journal of renal nutrition, 24(2), pp. 65-71. Elsevier 10.1053/j.jrn.2013.11.001

Text Toward individualized cholesterol-lowering treatment.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (606kB)

There is broad evidence that lowering low-density lipoprotein (LDL) cholesterol will reduce cardiovascular risk. However, in patients on maintenance hemodialysis treatment, lowering LDL cholesterol is not as effective in preventing cardiovascular complications as in the general population. Cholesterol is either endogenously synthesized or absorbed from the intestine. It has been suggested that the benefit of using statins to prevent atherosclerotic complications is less pronounced in people with high absorption of cholesterol. Recent data indicate that patients on hemodialysis have high absorption of cholesterol. Therefore, these patients may benefit from dietary counseling to reduce cholesterol intake, from functional foods containing plant sterols and stanols, and from drugs that interfere with intestinal absorption of sterols (i.e., ezetimibe, bile acid resins, and sevelamer). This review discusses cholesterol homeostasis and the perspective of personalized treatment of hypercholesterolemia in hemodialysis.

Interest & Impact

Downloads

10 since deposited on 09 Oct 2014
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item